Tyrogenex is studying X-82 in the APEX trial, a phase 2 study for wet AMD in Previously treated Eylea patients with X-82.

APEX is a randomized, double-masked, placebo-controlled, dose-finding phase 2 study being conducted at 37 clinical sites in the U.S.  The study is designed to evaluate the safety and efficacy of X-82 in the prevention of vision loss due to wet AMD.

For more information on the APEX study, visit clinicaltrials.gov.